Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Authors:
Maria Menichincheri Elena Ardini Paola Magnaghi Nilla Avanzi Patrizia Banfi Roberto Bossi Laura Buffa Giulia Canevari Lucio Ceriani Maristella Colombo Luca Corti Daniele Donati Marina Fasolini Eduard Felder Claudio Fiorelli Francesco Fiorentini Arturo Galvani Antonella Isacchi Andrea Lombardi Borgia Chiara Marchionni Marcella Nesi Christian Orrenius Achille Panzeri Enrico Pesenti Luisa Rusconi Maria Beatrice Saccardo Ermes Vanotti Ettore Perrone Paolo Orsini

J Med Chem 2016 Apr 30;59(7):3392-408. Epub 2016 Mar 30.

Oncology, Nerviano Medical Sciences Srl , Viale Pasteur 10, 20014 Nerviano, Milan, Italy.

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients. Within our ALK drug discovery program, we identified compound 1, a novel 3-aminoindazole active on ALK in biochemical and in cellular assays. Its optimization led to compound 2 (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models. Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types. Entrectinib is currently undergoing phase I/II clinical trial for the treatment of patients affected by ALK-, ROS1-, and TRK-positive tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.6b00064DOI Listing
April 2016

Publication Analysis

Top Keywords

lymphoma kinase
8
kinase alk
8
alk inhibitor
8
tumor types
8
anaplastic lymphoma
8
alk
6
entrectinib potent
4
potent orally
4
penetrant blood-brain
4
compound entrectinib
4
optimization led
4
led compound
4
efficiently penetrant
4
alk-dependent cell
4
inhibitor active
4
active alk-dependent
4
assays optimization
4
orally alk
4
lines efficiently
4
cell lines
4

Keyword Occurance

Similar Publications

Hydrogen-saturated saline mediated neuroprotection through autophagy via PI3K/AKT/mTOR pathway in early and medium stages of rotenone-induced Parkinson's disease rats.

Authors:
Zhaoqiang Zhang Xiao Sun Kun Wang Yang Yu Li Zhang Keping Zhang Jinglongfei Gu Xiaofan Yuan Guohua Song

Brain Res Bull 2021 Apr 7. Epub 2021 Apr 7.

Life science research center, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271000, China. Electronic address:

Some cardiovascular symptoms in the early stage of Parkinson's disease (PD) were related to degeneration of the rostral ventrolateral medulla (RVLM) catecholaminergic neurons. To date, little is known about the effects of hydrogen water on early stage of PD. Here, protective actions of hydrogen-saturated saline (HS) on rotenone-induced PD rats, as well as its underlying mechanisms were investigated. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.

Authors:
Hao Zeng Yujie Liu Weiya Wang Yuan Tang Panwen Tian Weimin Li

Ann Palliat Med 2021 Mar 22. Epub 2021 Mar 22.

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

An increasing number of anaplastic lymphoma kinase (ALK) gene fusion variants have been reported with the popularity of next-generation sequencing (NGS), such as striatin gene (STRN)-ALK, EMAP like 4 (EML4)-ALK and S1 RNA binding domain 1 (SRBD1)-ALK. The clinical outcomes of nonsmall cell lung cancer (NSCLC) patients improved dramatically with the treatment of tyrosine kinase inhibitors (TKIs), but responses to ALK-TKIs differ even for the same fusion variants with different breakpoints. The clinical effectiveness of ALK-TKIs on a new fusion variant needs to be evaluated. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.

Authors:
Xin Xu Ting Wei Weijie Zhong Rosalind Ang Ye Lei Hui Zhang Qingshan Li

Cancer Cell Int 2021 Apr 7;21(1):195. Epub 2021 Apr 7.

Department of Hematology, Guangzhou Red Cross Hospital, Jinan University, No. 396 Tongfuzhong Road, Haizhu District, 510220, Guangzhou, Guangdong, People's Republic of China.

Background: Non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB-DLBCL) has worse clinical outcome than GCB-DLBCL, and some relapsed/refractory non-GCB-DLBCL (R/R non-GCB-DLBCL) are even resistant to CD20 monoclonal antibody (rituximab). Bruton's tyrosine kinase inhibitors (BTKis) are new drugs for B-cell lymphoma. BTKis can promote apoptosis of DLBCL by inactivating nuclear transcription factor κB (NFκB) signaling pathway. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

The Protective Effects of Apremilast Against Oxygen-Glucose Deprivation/Reperfusion (OGD/R)-Induced Inflammation and Apoptosis in Astroglia Mediated by CREB/BDNF.

Authors:
Hang Yin Hao Qin Tiantian Wang Qiang Zhuang Qixia Yang

Neurotox Res 2021 Apr 7. Epub 2021 Apr 7.

Department of Pharmacy, Zaozhuang Municipal Hospital, Zaozhuang, 277100, Shandong, China.

Oxygen-glucose deprivation and reoxygenation (OGD/R)-induced impairment of astrocytes may lead to neuronal dysfunction in the central nervous system (CNS). Apremilast is a phosphodiesterase 4 (PDE4) inhibitor primarily used for the treatment of psoriasis and psoriatic arthritis that has demonstrated certain neuroprotective properties. PDE4 is an isoenzyme that degrades 3'-5'-cyclic adenosine monophosphate (cAMP), which serves as a neuroprotective agent by promoting neuronal recovery through protein kinase (PKA)-mediated phosphorylation of cAMP response element-binding protein (CREB) and subsequent expression of the neurotrophic factor brain-derived neurotrophic factor (BDNF) and anti-apoptotic B cell lymphoma (Bcl-2). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.

Authors:
Takuya Harada Hiromi Iwasaki Tsuyoshi Muta Shingo Urata Aiko Sakamoto Kentaro Kohno Ken Takase Tomoya Miyamura Takuya Sawabe Hideki Asaoku Kensuke Oryoji Tomoaki Fujisaki Yasuo Mori Goichi Yoshimoto Masahiro Ayano Hiroki Mitoma Toshihiro Miyamoto Hiroaki Niiro Hidetaka Yamamoto Yumi Oshiro Hiroaki Miyoshi Koichi Ohshima Morishige Takeshita Koichi Akashi Koji Kato

Br J Haematol 2021 Apr 6. Epub 2021 Apr 6.

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.

Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased. However, whether ts/bDMARDs are associated with the development and clinicopathological features of MTX-associated lymphoproliferative disorder (MTX-LPD) in patients with RA remains unknown. Therefore, we evaluated the clinical outcomes of 121 patients with MTX-LPD. Read More

View Article and Full-Text PDF
April 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap